Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label maintenance study of sodium zirconium cyclosilicate in hyperkalemia
NL-OMON43860Phase 3Active, not recruiting
- Sponsor
- ZS Pharma
- Start
- Jul 2015
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of sodium zirconium cyclosilicate in hyperkalemia, sponsored by ZS Pharma. Primary endpoint: Safety and tolerability. Started Jul 2015; status: active, not recruiting.
02
Drugs
sodium zirconium cyclosilicate
03
Conditions
hyperkalemia
Beyond the preview
Go deeper on NL-OMON43860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43860.